Primmune Therapeutics Is Developing An Orally Administered Tlr7 Agonist To Stimulate Innate Immunity In Cancer Immunotherapyour Goal Is To Improve The Response Rate Of Patients To Current And Future Immunotherapy Medicines
| Company Name | Primmune Therapeutics Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
Enter your address and we will specify the offer for your area.